Heart, Lung and Circulation最新文献

英文中文

Are Women a Different Species When it Comes to Chest Pain: A Decade of Data Analysis from a Victorian Rapid Access Chest Pain Clinic 女性是否是胸痛患者中的另类：维多利亚州快速胸痛门诊十年来的数据分析

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.06.085

引用次数: 0

A Prospective Comparative Analysis of 2D and 3D Echocardiographic Imaging of the Left Atrial Appendage 左房阑尾二维和三维超声心动图成像的前瞻性对比分析

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.06.075

引用次数: 0

Acetate Lowers Human Blood Pressure Whether Administered Directly or Produced Indirectly in the Colon 无论是直接给药还是在结肠中间接产生，醋酸盐都能降低人体血压

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.06.026

引用次数: 0

Association Between Left Ventricular Outflow Tract Velocity Time Integral, Ejection Fraction, and Mortality in an Undifferentiated Cohort of Hospitalised Patients 无差别住院患者队列中左心室流出道速度时间积分、射血分数与死亡率之间的关系

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.06.089

引用次数: 0

Recurrent Takotsubo Syndrome: How Frequent, and How Does It Present? 复发性 Takotsubo 综合征：频率有多高，如何表现？

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.02.008

Background

Recurrent Takotsubo syndrome (TS) is not uncommon but experience with TS recurrence is inherently limited by the infrequency of the condition itself and incomplete long-term follow-up. There is limited published data on the clinical features and outcomes of patients with recurrent TS. We aimed to describe the clinical characteristics and outcomes of patients with recurrent TS in a large Auckland cohort.

Method

The clinical profile, in-hospital, and long-term outcomes were prospectively assessed in consecutive patients with recurrent TS presenting to Auckland’s three major hospitals between January 2006 and January 2023.

Results

During the study period, 472 TS patients were identified. Of the 467 patients discharged alive after the index event, 45 (9.6%) patients (mean age 62.3±11.0 years), all women, experienced recurrent TS. Median time interval from index event to the first recurrence was 3.14 years (range 27 days to 13.8 years). In 27 (60%) of the 45 patients, the subsequent events involved a stressor (physical triggers, n=8; emotional triggers, n=19). The stressor type differed between the index and recurrent event in 18 (40%) of the 45 patients. Thirteen (28.9%) had a different echocardiographic variant of TS at first recurrence. All patients with recurrent TS were discharged alive. Four patients died late after discharge from the first recurrence, all but one from a non-cardiac cause.

Conclusions

One in 10 patients with TS experience recurrent events. These may occur many years later, and both the stressor type and the echocardiographic variant may be different at the recurrent event.

背景：复发性塔克氏综合征（TS）并不少见，但由于这种疾病本身并不常见，而且长期随访也不完整，因此有关 TS 复发的经验受到了固有的限制。关于复发性 TS 患者的临床特征和预后，已发表的数据非常有限。我们旨在描述奥克兰大型队列中复发 TS 患者的临床特征和预后：方法：我们对2006年1月至2023年1月期间在奥克兰三大医院就诊的连续复发性TS患者的临床概况、院内情况和长期疗效进行了前瞻性评估：研究期间共发现了472名TS患者。在指数事件后出院的 467 名存活患者中，有 45 名（9.6%）患者（平均年龄为 62.3±11.0 岁）复发了 TS，均为女性。从发病到首次复发的中位时间间隔为 3.14 年（范围为 27 天至 13.8 年）。在 45 名患者中，有 27 人（60%）的后续事件涉及应激源（身体诱因，8 人；情绪诱因，19 人）。在 45 名患者中，有 18 人（40%）的指数事件和复发事件的压力源类型不同。13名患者（28.9%）在首次复发时有不同的 TS 超声心动图变异。所有复发 TS 的患者均活着出院。四名患者在首次复发出院后晚期死亡，除一人外，其余均死于非心脏原因：结论：每10例TS患者中就有1例复发。结论：每 10 例 TS 患者中就有 1 例会出现复发，这些复发可能发生在多年之后，复发时的应激源类型和超声心动图变异都可能不同。

{"title":"Recurrent Takotsubo Syndrome: How Frequent, and How Does It Present?","authors":"","doi":"10.1016/j.hlc.2024.02.008","DOIUrl":"10.1016/j.hlc.2024.02.008","url":null,"abstract":"<div><h3>Background</h3><p>Recurrent Takotsubo syndrome (TS) is not uncommon but experience with TS recurrence is inherently limited by the infrequency of the condition itself and incomplete long-term follow-up. There is limited published data on the clinical features and outcomes of patients with recurrent TS. We aimed to describe the clinical characteristics and outcomes of patients with recurrent TS in a large Auckland cohort.</p></div><div><h3>Method</h3><p>The clinical profile, in-hospital, and long-term outcomes were prospectively assessed in consecutive patients with recurrent TS presenting to Auckland’s three major hospitals between January 2006 and January 2023.</p></div><div><h3>Results</h3><p>During the study period, 472 TS patients were identified. Of the 467 patients discharged alive after the index event, 45 (9.6%) patients (mean age 62.3±11.0 years), all women, experienced recurrent TS. Median time interval from index event to the first recurrence was 3.14 years (range 27 days to 13.8 years). In 27 (60%) of the 45 patients, the subsequent events involved a stressor (physical triggers, n=8; emotional triggers, n=19). The stressor type differed between the index and recurrent event in 18 (40%) of the 45 patients. Thirteen (28.9%) had a different echocardiographic variant of TS at first recurrence. All patients with recurrent TS were discharged alive. Four patients died late after discharge from the first recurrence, all but one from a non-cardiac cause.</p></div><div><h3>Conclusions</h3><p>One in 10 patients with TS experience recurrent events. These may occur many years later, and both the stressor type and the echocardiographic variant may be different at the recurrent event.</p></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1443950624001240/pdfft?md5=c5a33090e0545d71dc9f3c463cb5b118&pid=1-s2.0-S1443950624001240-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140329775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Current Landscape of Ventricular Tachycardia Trials: A Systematic Review of Registered Studies 室性心动过速试验的现状：注册研究的系统性回顾。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.01.041

Background

Although there are evolving techniques and technologies for treating ventricular tachycardia (VT), the current landscape of clinical trials for managing VT remains understudied.

Objective

The objective of this study was to provide a systematic characterisation of the interventional management of VT through an analysis of the ClinicalTrials.gov, clinicaltrialsregister.eu, anzctr.org.au and chictr.org.cn databases.

Methods

We queried all phase II to IV interventional trials registered up to November 2023 that enrolled patients with VT. Published, completed but unpublished, terminated, or ongoing trials were included for final analysis.

Results

Of the 698 registered studies, 135 were related to VT, with 123 trials included in the final analysis. Among these trials, 25 (20%) have been published, enrolling a median of 35 patients (interquartile range [IQR] 20–132) over a median of 43 months (IQR 19–62). Out of the published trials, 14 (56%) were randomised, and 12 (48%) focused on catheter ablation. Twenty-two (18%) have been completed but remain unpublished, even after a median of 36 months (IQR 15–60). Furthermore, 27 (22%) trials were terminated or withdrawn, with the most common cause being poor enrolment. Currently, 49 (40%) trials are ongoing and novel non-ablative technologies, such as radioablation and autonomic modulation, account for 35% and 8% of ongoing trials, respectively.

Conclusions

Our analysis revealed that many registered trials remain unpublished or incomplete, and randomised controlled trial evidence is limited to only a few studies. Furthermore, many ongoing trials are focused on non-catheter ablation-based strategies. Therefore, larger pragmatic trials are needed to create stronger evidence in the future.

背景：尽管治疗室性心动过速（VT）的技术和科技在不断发展，但目前治疗 VT 的临床试验情况仍未得到充分研究：本研究的目的是通过分析 ClinicalTrials.gov、clinicaltrialsregister.eu、anzctr.org.au 和 chictr.org.cn 数据库，对 VT 的介入治疗进行系统描述：我们查询了截至 2023 年 11 月注册的所有纳入 VT 患者的 II 至 IV 期介入性试验。最终分析纳入了已发表、已完成但未发表、已终止或正在进行的试验：在登记的 698 项研究中，135 项与 VT 相关，其中 123 项纳入最终分析。在这些试验中，有 25 项（20%）已发表，入组患者中位数为 35 人（四分位数间距 [IQR] 20-132），入组时间中位数为 43 个月（IQR 19-62）。在已发表的试验中，14 项（56%）是随机试验，12 项（48%）侧重于导管消融。有 22 项（18%）试验已经完成，但仍未发表，即使中位数为 36 个月（IQR 15-60）。此外，有 27 项（22%）试验被终止或撤销，最常见的原因是入选率低。目前，有49项（40%）试验正在进行中，而新型非消融技术，如放射性消融和自主神经调节，分别占正在进行的试验的35%和8%：我们的分析表明，许多已登记的试验仍未公布或不完整，随机对照试验的证据也仅限于少数几项研究。此外，许多正在进行的试验都集中在非导管消融策略上。因此，未来需要更大规模的实用性试验来提供更有力的证据。

{"title":"The Current Landscape of Ventricular Tachycardia Trials: A Systematic Review of Registered Studies","authors":"","doi":"10.1016/j.hlc.2024.01.041","DOIUrl":"10.1016/j.hlc.2024.01.041","url":null,"abstract":"<div><h3>Background</h3><p>Although there are evolving techniques and technologies for treating ventricular tachycardia (VT), the current landscape of clinical trials for managing VT remains understudied.</p></div><div><h3>Objective</h3><p>The objective of this study was to provide a systematic characterisation of the interventional management of VT through an analysis of the <em>C</em><em>linicalTrials.gov, clinicaltrialsregister.eu, anzctr.org.au</em> and <em>chictr.org.cn</em> databases.</p></div><div><h3>Methods</h3><p>We queried all phase II to IV interventional trials registered up to November 2023 that enrolled patients with VT. Published, completed but unpublished, terminated, or ongoing trials were included for final analysis.</p></div><div><h3>Results</h3><p>Of the 698 registered studies, 135 were related to VT, with 123 trials included in the final analysis. Among these trials, 25 (20%) have been published, enrolling a median of 35 patients (interquartile range [IQR] 20–132) over a median of 43 months (IQR 19–62). Out of the published trials, 14 (56%) were randomised, and 12 (48%) focused on catheter ablation. Twenty-two (18%) have been completed but remain unpublished, even after a median of 36 months (IQR 15–60). Furthermore, 27 (22%) trials were terminated or withdrawn, with the most common cause being poor enrolment. Currently, 49 (40%) trials are ongoing and novel non-ablative technologies, such as radioablation and autonomic modulation, account for 35% and 8% of ongoing trials, respectively.</p></div><div><h3>Conclusions</h3><p>Our analysis revealed that many registered trials remain unpublished or incomplete, and randomised controlled trial evidence is limited to only a few studies. Furthermore, many ongoing trials are focused on non-catheter ablation-based strategies. Therefore, larger pragmatic trials are needed to create stronger evidence in the future.</p></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1443950624001215/pdfft?md5=0c26455bdf81f3bfca6e2ddf430df66f&pid=1-s2.0-S1443950624001215-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141183475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimal Percutaneous Treatment of Ostial Left Anterior Descending Artery—Crossing is the Route to Perfection! 经皮治疗左前降支动脉的最佳方法--交叉是通往完美的途径！

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.07.004

引用次数: 0

The Impact Of Spatial Distribution of Likely Pathogenic/Pathogenic Variants on Clinical Outcomes in LMNA Cardiomyopathy—An International, Multi-Centre Registry-Based Study 可能致病/致病变异体的空间分布对 LMNA 心肌病临床结果的影响--一项基于多中心登记的国际研究

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.06.021

引用次数: 0

Platelet Derived Growth Factor-AB Modulates Post Infarct Myocardium Leading to Long Term Improvement in Cardiac Function 血小板衍生生长因子-AB 可调节梗死后心肌，从而长期改善心功能

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/j.hlc.2024.06.006

引用次数: 0

Title Page 标题页

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Heart, Lung and Circulation

Pub Date : 2024-08-01 DOI: 10.1016/S1443-9506(24)01760-8

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Heart, Lung and Circulation

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀